If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you


No announcement yet.

PTSMA is a new therapeutic option


About the Author


hcma Find out more about hcma
  • Filter
  • Time
  • Show
Clear All
new posts

  • PTSMA is a new therapeutic option

    Copyright 2003 Health & Medicine Week via NewsRx.com and NewsRx.net
    Health & Medicine Week

    October 27, 2003


    LENGTH: 444 words

    HEADLINE: CARDIOMYOPATHY: Echocardiography shows sustained improvement in PG,
    septal walls


    Echocardiography shows sustained improvement in PG, septal, and left
    ventricular posterior wall thicknesses.

    According to a study from Japan, "Percutaneous transluminal septal myocardial
    ablation (PTSMA) is a new therapeutic option for patients with hypertrophic
    obstructive cardiomyopathy (HOCM).

    "In the present study, the acute and follow-up results of PTSMA were
    evaluated. From August 1997 to March 2003, 27 medically refractory patients (New
    York Heart Association (NYHA) functional class 2.9plusmn0.6) with HOCM underwent
    PTSMA," wrote E. Tsuchikane and colleagues, Osaka Medical Center, Cancer &
    Cardiovascular Diseases, Department of Cardiology.

    "The target septal branch was determined by probationary ballooning in three
    and by myocardial contrast echocardiography in 24 patients. The mean resting
    left ventricular outflow tract pressure gradient (PG) was reduced from
    70plusmn44 to 24plusmn22 mmHg (p<.0001); the peak concentration of creatine
    kinase was 1,545plusmn686 IU/L," the researchers wrote.

    "Although transient trifascicular block was observed in 14 patients,
    permanent pacemaker implantation was not required. There were no major adverse
    cardiac events during the hospital stay; the mean clinical follow-up was
    2.2plusmn1.7 years. Repeated PTSMA was needed in one patient; however,
    symptomatic improvement had been well preserved in all patients (NYHA class
    1.2plusmn0.4)," the researchers stated.

    The researchers concluded: "Follow-up echocardiographic examination showed
    sustained improvement in PG, septal, and left ventricular posterior wall
    thicknesses, and the grade of systolic anterior movement and regurgitation of
    the mitral valve. PTSMA is a safe and effective therapeutic option for medically
    refractory patients with HOCM."

    Tsuchikane and colleagues published their study in Circulation Journal
    (Percutaneous transluminal septal myocardial ablation for hypertrophic
    obstructive cardiomyopathy - Initial and follow-up results in the first 27
    patients. Circ J, 2003;67(9):763-767).

    For more information, contact E. Tsuchikane, Osaka Medical Center, Cancer &
    Cardiovascular Diseases, Department of Cardiology, Higashinari Ku, 1-3-3
    Nakamichi, Osaka 5378511, Japan.

    Publisher contact information for the Circulation Journal is: Blackwell
    Publishing Asia, 54 University St., PO Box 378, Carlton, Victoria 3053,

    The information in this article comes under the major subject area of Medical

    This article was prepared by Health & Medicine Week editors from staff and
    other reports.


    LOAD-DATE: October 24, 2003